Reuters Novartis has agreed to buy AveXis for $8.7 billion. The $218-per-share cash deal represents a 72% premium to AveXis's 30-day volume-weighted average stock price. The deal is expected to close in mid-2018. (Reuters) - Swiss drugmaker Novartis is movingâ€¦
